NOR-MS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Cladribine
DNA inhibitor
What it measured
Main measures
The primary endpoint is the number of new or enlarging cerebral MRI T2 lesions per patient from week 12 to week 96.
MRI lesions
Other measures (1)
- Number of new or enlarging cerebral MRI T2 lesions per patient from week 12 to week 48
MRI lesions
Who could take part
Relapsing MS
Inclusion: − Age between 18 and 65 years Exclusion: − Any contraindication or increased risk of side-effects from rituximab or cladribine (such as ongoing acute or chronic infection, live vaccination less than 4 weeks before start of treatment or planned live vaccination, immunocompromised, previous or active malignant disease, ongoing glucocorticoid treatment or allergy against any products of the medication)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of RMS.
Loading reviews and guidelines…
Related trials
- Operetta III
Phase 2 · Not yet recruiting
Still running
- SOLI
Recruiting
Still running
- SONATA-MS
Recruiting
Still running
- HiHat
Phase 2 · Recruiting
Still running
- REDIFINE MS
Recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
History
Started
May 2019
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error